Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RPBIF: Plan of Arrangement. Shareholders will receive $1.12 per common share in cash.
FINRA deleted symbol:
http://otce.finra.org/DLDeletions
RPBIF NOW LISTED ON ZICA IHUB BOARD
http://investorshub.advfn.com/***Zika-virus-%28Shorts-and-Longs%29-%28ZIKA%29***-30666/
RPBIF one for 20 reverse split:
http://www.otcbb.com/asp/dailylist_detail.asp?d=09/25/2012&mkt_ctg=OTCBB
I know little about them and as I said. The inside buy triggered my look at their website and so on. THis guy seems to have an ability to increase value, then sell. Looks like it might be his first or second time in a public Company. By Good is good no matter where you put it. Seems like he surrounded himself with talent too.
On a general principal I go with leaders like this and it almost always pays off. It is no a flipper for sure. But one to buy as low as possible, maybe 4 cets and see 3 - 5 bucks in 2 - 4 years. A good payday long. If you get enough like that goping, there is always one to sell high every few months. That is my long term goal.
Thanks for the response about what excites you about Response.
I will be watching to see if a plan emerges that has hope of growth in their main product sales. Approx $3M in sales per quarter is not chicken feed, but I want to see a plan forward.
Urche
Mr. Purvin is a member of the Board of Directors at Cardica, Inc. Cardica markets a unique coronary bypass anastomosis connection device to cardiothoracic surgeons, worldwide, and is currently developing a unique, multi-staple-firing surgical stapler line. Mr. Purvin is Chair of Cardica Compensation Committee and is a member of its Audit and Finance Committees.
Cant find any reason to post this on another Companies web site other than to let everyone know that they will suck that company into their own. Especially the multi stapler.
Just read it a little more, without checked out more of the TEAM, looks like he has brought in help too. Very successful CFO and sales leader.
Wondering where the bottom is ????
Seen the insider buy, so I did my work. Looks like they have a new CEO. Go read about him and where he has been and what he has done. Basically, he has done very well with other companies, Is on the board of another one, brings together good prodcts. Makes the Companies valuable and sells them. COnsidering where this one started, I just think it has a future and is priced right now. I cant afford any of it yet so I am hoping it stays low for a couple more months.
It should take them that long to get things going in the right direction. Just check out the web site and officers, etc.
I have stopped following this company after years of thinking it was promising.
What holds your interest in Response for the future?
Urche
This is one to put on the radar. Do your own DD
Are you buying some?
I have lost track of near term catalysts for Response.
It seems their market niche is pushing mostly outside US, where it is less interesting or possible for me to follow and understand.
Urche
former long RPBIF
Response Biomedical Corporation Announces $8 Million Rights Offering
| 6:02 PM |
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68991429
Response Biomedical Pre-Announces 2009 Year-End Revenues
Record Revenues for the Year
Conference Call on March 25th to discuss full results
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company expects to report annual revenues of approximately $10 million in 2009, as compared to $5.876 million in 2008. The Company will host a conference call and announce complete fourth quarter and year-end financial results on March 25th.
“This is an exciting time in the Company’s history, with 2009 being a record year for overall revenue. These results are consistent with our plan, which anticipates another near-doubling of revenues in 2010 and becoming cash flow positive during the 4th quarter of 2010”
“This is an exciting time in the Company’s history, with 2009 being a record year for overall revenue. These results are consistent with our plan, which anticipates another near-doubling of revenues in 2010 and becoming cash flow positive during the 4th quarter of 2010,” said S. Wayne Kay, Chief Executive Officer. “This exciting revenue growth in the rapid point-of-care market space is in great part the result of our blue chip partners, Roche Diagnostics, 3M Health Care and Shionogi Limited, together with our own efforts in China. Roche Diagnostics launched our cardiac line earlier in 2009 in the U.S. and 3M continued its launch of the Flu A+B product in the U.S., also adding our RAMP® RSV test to the platform this past October, as well. We look forward to discussing our progress this week, as we attend the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.”
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
The RAMP® system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP® clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through our commercial partners, Roche and 3M Health Care respectively.
In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.
Response Biomedical is a publicly-traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
Response Biomedical Receives European Patent Notice of Allowance for Key Component of Immunoassay Intellectual Property
VANCOUVER--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced today that the Company has received a Notice of Allowance from the European Patent Office for the patent entitled “Sensitive Immunochromatographic Assay”, referred to as the “Fong Patent”. This critical patent protects key aspects of Response Biomedical’s lateral flow immunoassays conducted with the proprietary RAMP® testing platform.
“Our market expansion plans, in conjunction with our key partners, will have significant focus on the European Union. We expect to see RAMP® continue to set new performance standards in rapid diagnostic testing by providing lab quality information in minutes.”
“The ‘Fong Patent’ is a pivotal piece of our intellectual property portfolio and we are very pleased with the European Patent Office’s (EPO) decision to grant our claims in support of our technology platform,” said S. Wayne Kay, Chief Executive Officer. “Our market expansion plans, in conjunction with our key partners, will have significant focus on the European Union. We expect to see RAMP® continue to set new performance standards in rapid diagnostic testing by providing lab quality information in minutes.”
The Fong Patent describes various methods to improve assay performance through the correction of intrinsic variability in lateral flow assays, which provides more precise results than typical lateral flow methods. This patent has been issued in the United States and Australia and is pending in China, Hong Kong, Japan and Canada. Recently the Company announced it had received further continuation of the Fong Patent from the United States Patent and Trademark Office for the competitive claims, significantly expanding the U.S. intellectual property to allow coverage for small molecules. The Company is currently seeking additional partners to develop products covered under its portfolio of patent protection.
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
The RAMP® system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP® clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through our commercial partners, Roche and 3M Health Care respectively.
In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.
Response Biomedical is a publicly-traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
Response Biomedical Goes Live With Pilgrim Software
January 5, 2010
Tampa, FL - Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, recently announced that Response Biomedical, a producer of rapid on-site diagnostic tests, has gone live with Pilgrim's solution for complaints management to help expedite complaint handling while ensuring ongoing regulatory compliance.
Pilgrim's Complaints Management solution provides Response Biomedical with a single source data center for tracking and managing all complaints within its facilities. It enables rapid complaint resolution through its e-mail notifications, and tracking and escalation capabilities; improves the management of customer communication; and, ensures regulatory and industry compliance.
Response chose to automate its complaints processing and eliminate manual systems allowing for easier tracking and trending analyses. It turned to Pilgrim's On Demand solution to help reduce the time required of its limited in-house IT staff to conduct a full implementation, including validation to comply with 21 CFR Part 11 requirements.
"We saw Pilgrim's SAS 70-certified hosted model as the right solution for our needs," said Marcia Zucker, Ph.D., Response Biomedical's director of Clinical Support. "We recently moved into a new facility, and have limited service space for servers, so choosing to implement Pilgrim's solution on-demand frees up both hardware requirements and allows our IT team more time to address other key projects."
Pilgrim's Complaints Management solution will enable Response to more efficiently manage customer complaints and document responses to incidents. Because of its inherent scalability, the solution also can be expanded should Response add users, and it can be easily integrated with other automated quality and compliance management solutions. Even with expansion and integration, the On Demand model helps keep the company's IT costs to a minimum, allowing it to increase its overall revenues.
"Our Complaints Management solution is the right software for life sciences companies like Response Biomedical because it takes the worry out of their complaint handling and overall quality assurance efforts, and enables them to redirect their resources toward other challenges facing their industry," said Prashanth Rajendran, Pilgrim's Chief Operating Officer. "Implementing it on-demand further expedites the ROI of the solution."
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. RAMP® clinical tests are commercially available for the early detection of heart attack and congestive heart failure. In late 2006, the Company formed a strategic alliance with 3M Company to commercialize rapid infectious disease tests. In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
About Pilgrim Software, Inc.
Pilgrim Software, Inc. is a world-leading provider of Enterprise Compliance and Quality Management solutions for global organizations. Named 2007 & 2008 North American Enterprise Compliance & Quality Management Company of the Year by Frost & Sullivan, Pilgrim helps organizations manage industry and regulatory compliance, reduce manufacturing costs and improve customer satisfaction.
SOURCE: Pilgrim Software Inc.
http://www.pharmaceuticalonline.com/article.mvc/Response-Biomedical-Goes-Live-With-Pilgrim-0001?VNETCOOKIE=NO
Why do you post about Medica? Can rpbif make any headway by exhibiting there? First time on for me, but I see it is not busy here. I will come on and keep you company. Any special things I should know? Shareholder for a long time at much higher prices..For the life of me, I cannot understand why this stock is so low.
Medica 18-21.11.09 in Düsseldorf Germany
http://www.medica-tradefair.com/cipp/show,fair,medcom2009/lang,2/oid,28139/exh_id,4672/~/Web-ExhDatasheet/exh_datasheet
Exhibitors are there :
Response Biomedical
3M
Roche Diagnostics
conf call
A few notes from the conf call added to the terse statements from management in the PR.
1) Almost all the fine growth in revenue reported was from Asia, esp China. US sales (mostly BNP) have been nearly flat and disappointing.
2) However CEO expressed satisfaction with the 3M and Roche relationships and is optimistic about a new marketing strategy by Roche that will start late this year. There will be more marketing of RAMP tests directly to clinics who order the tests (such as cardiologists) rather than hospital labs.
3) New business opportunities seem to abound, with a new TB test that is being evaluated by a Swiss organization (?FIND?) that receives funding from the Gates Foundation. Roche and 3M are also evaluating some new tests. I doubt these new opportunities would affect the bottom line initially, but at least would expect the increased development costs would be funded by the partners.
4) Enough cash still exists to go to Q4 2010 which, is about the time that profitability can be projected. Although it was not said in the CC, I would still expect another dilutive financing unless a rich deal with a partner is struck.
Considering the whole story and the current price, it seems a value to me and I added to my position yesterday.
Urche
Response Biomedical Corporation Announces Third Quarter Results
* Total revenues double over last year’s comparable nine months
* Clinical products revenue up 139% over last year’s comparable nine months
VANCOUVER--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced financial results for the third quarter and nine months ended September 30, 2009.
Total revenues for the three and nine month periods ended September 30, 2009 increased 39% and 106% to $2,047,523 and $7,495,339, respectively, compared to $1,471,130 and $3,641,766 for the same periods in 2008. Given the success of our commercial partners’ efforts, clinical products revenue showed the largest growth at 62% and 139% to $1,688,423 and $5,236,438 for the three and nine month periods ended September 30, 2009, respectively, compared to $1,040,649 and $2,191,409 for the same periods in 2008.
Net loss for the three and nine month periods ended September 30, 2009 was reduced by 14% and 38% to $3,177,221 and $6,807,623, respectively, compared to $3,684,602 and $10,969,207 for the same periods in 2008. Expenses were reduced by 15% and 29% to $2,813,195 and $7,552,556, respectively, for the three and nine month periods ended September 30, 2009, compared to $3,294,694 and $10,636,832 for the same periods in 2008.
“We are on track to conclude our best year ever, with total revenues at September 30, 2009 well in excess of total revenues for all of 2008. As we work with our partners and global distributors to introduce the RAMP® technology to a growing international market, we see this trend continuing in 2010 and beyond,” said S. Wayne Kay, Chief Executive Officer. “Looking at our strengthened cash position, we had approximately $7.5 million in cash and cash equivalents as at September 30, 2009, compared to $2.3 million as at December 31, 2008,” said S. Wayne Kay, Chief Executive Officer. “Our working capital as at September 30, 2009 was approximately $9.0 million compared to $2.9 million as at December 31, 2008. As you can see, we continue to show strong revenue growth, quarter over quarter when compared to revenues from last year.”
Conference Call Information
Response Biomedical management will host an analyst conference call beginning at 10:00 a.m. (Eastern Time) today to discuss these results and other corporate matters. During the conference call, the Company may discuss and answer questions concerning business and financial developments and trends.
The analyst conference call may be accessed by dialing 1-416-981-9000 (domestic and international) or 1-800-954-0691 (toll free in North America). An access code is not required. It is also available to listen via Web cast at http://www.snwebcastcenter.com/event/?event_id=589. An archive of the call will be available from the same link approximately two hours after the live call has concluded and will be accessible for 30 days.
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
The RAMP® system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP® clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through our commercial partners, Roche and 3M Health Care respectively.
In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
Response Biomedical to Release Q3 Financial Results on November 10, 2009
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20091103005635&newsLang=en
© Business Wire 2009
2009-10-27 19:12:04
New 3M Rapid Detection RSV Test Offers Objective Automated Results
http://www.pr-inside.com/new-3m-rapid-detection-rsv-test-r1549647.htm
0
Obama declares swine flu national emergency
Order could speed up treatments by waiving certain medical standards
msnbc.com news services
updated 3:06 p.m. ET Oct. 24, 2009
WASHINGTON - President Barack Obama has signed a proclamation declaring swine flu a national emergency, the White House said Saturday. The order gives his health chief the power to let hospitals move emergency rooms offsite to speed treatment and protect noninfected patients.
Administration officials said the declaration was a pre-emptive move designed to make decisions easier when they need to be made. Officials said the move was not in response to any single development.
Health and Human Services chief Kathleen Sebelius now has authority to bypass federal rules when opening alternative care sites, such as offsite hospital centers at schools or community centers if hospitals seek permission.
Some hospitals have opened drive-thrus and drive-up tent clinics to screen and treat swine flu patients. The idea is to keep infectious people out of regular emergency rooms and away from other sick patients.
Hospitals could modify patient rules — for example, requiring them to give less information during a hectic time — to quicken access to treatment, with government approval, under the declaration.
It also addresses a financial question for hospitals — reimbursement for treating people at sites not typically approved. For instance, federal rules do not allow hospitals to put up treatment tents more than 250 yards away from the doors; if the tents are 300 yards or more away, typically federal dollars won't go to pay for treatment.
Administration officials said those rules might not make sense while fighting the swine flu, especially if the best piece of pavement is in the middle of a parking lot and some medical centers already are putting in place parts of their emergency plans.
The national emergency declaration was the second of two steps needed to give Sebelius extraordinary powers during a crisis.
On April 26, the administration declared swine flu a public health emergency, allowing the shipment of roughly 12 million doses of flu-fighting medications from a federal stockpile to states in case they eventually needed them. At the time, there were 20 confirmed cases in the U.S. of people recovering easily. There was no vaccine against swine flu, but the CDC had taken the initial step necessary for producing one.
More widespread than ever
Swine flu is more widespread now than it's ever been, and has resulted in more than 1,000 U.S. deaths so far, officials said Friday.
Flu illnesses are as widespread now as they are at the winter peak of normal flu seasons, Thomas Frieden, director for the Centers for Disease Control and Prevention, told reporters. "To be basically in the peak of flu season in October is extremely unusual," he said.
"We expect that influenza will occur in waves and we can't predict how high, how far or how long the wave will go or when the next will come," he added.
"Many millions" of Americans have had swine flu so far, according to an estimate he gave at a Friday press conference. The government doesn't test everyone to confirm swine flu so it doesn't have an exact count.
Frieden updated some other estimates, too, saying there have been more than 20,000 hospitalizations.
Nearly 100 swine flu deaths in children have been reported, CDC officials also said.
Forty-six states now have widespread flu activity. The only states without widespread flu are Connecticut, Hawaii, New Jersey and South Carolina. There are at least two different types of flu causing illnesses; tests from about 5,000 patients suggest that nearly all the flu cases are swine flu.
'Frustrating' production delays
This year's seasonal flu vaccine won't protect against swine flu; a separate swine flu vaccine is needed. Vaccine production takes several months, and the work on seasonal vaccine was already well under way when swine flu was first identified in April. It was too late for the swine flu virus to be included in the seasonal doses.
Because of swine flu vaccine production delays, the government has backed off initial, optimistic estimates that as many as 120 million vaccine doses would be available by mid-October. As of Wednesday, only 11 million doses had been shipped to health departments, doctor's offices and other providers across the country, CDC officials said.
"It's frustrating to all of us. We wish there were more vaccine available," Frieden said.
The flu virus has to be grown in chicken eggs, and the yield hasn't been as high as was initially hoped, CDC officials explained. "Even if you yell at them, they don't grow faster," Frieden said.
He added that 5 million new doses became available in the past week, and vaccine should be more plentiful soon.
Much of the vaccine currently available is a nasal spray from AstraZeneca's unit MedImmune.
The Obama administration has ordered vaccine from five manufacturers: Sanofi-Aventis SA, CSL Ltd, Novartis AG, GlaxoSmithKline and AstraZeneca's MedImmune.
Also Friday, federal health officials said more Americans have been vaccinated against seasonal flu this fall than ever before by this time of year.
Sixty million people have gotten the winter flu vaccine — probably because they're paying more attention to flu warnings in general, thanks to swine flu. It's an unprecedented number of seasonal flu shots for October; most usually aren't given until later in the fall.
Part of it is due to supply: There are already 85 million doses of seasonal flu vaccine available, a much larger amount than usual for this early in the fall. Most years, roughly 100 million doses are used during the season.
But a big factor probably is that swine flu is drawing attention to public health warnings that seasonal flu is also a deadly illness that can be prevented through vaccinations, said Joe Quimby, a spokesman for the CDC.
"There's been a heightened awareness in the American public due to H1N1 this year," said Quimby.
Global figures
Also Friday, the World Health Organization reported more than 414,000 laboratory confirmed cases of H1N1 worldwide, with nearly 5,000 deaths.
But the Geneva-based health agency noted that the figures were only the tip of the iceberg.
"As many countries have stopped counting individual cases, particularly of milder illness, the case count is significantly lower than the actual number of cases that have occurred," WHO said.
http://www.msnbc.msn.com/id/33459423/ns/health-cold_and_flu/
I don't think that i'm alone here, but everyone should be share, everything about Response.
10Q should be great....
Don't think you are alone.
There is at least one other reader and long time holder of this company. Even though I think there is some promise for this company, and I think the share price does not reflect the potential, it is below the radar of most investors. So, it is hard to be optimistic about the future until substantial profits and attention from US analysts develops.
There's a lot of activity going on here, but things move incredibly slow here, so we hurry up and wait...
There are a few key things happening right now thought that will help move things forward, one is the annocement today .I can see a new sense of urgency to get things accomplished.
One step at a time...
I can't understand why this Stock is so extremly undervalued........
Global Biotech Investing - Response Biomedical sample depot admission 12:06 06.10.09 Endingen (aktiencheck.de AG) - which experts of " Global Biotech Investing" takes up the Response Biomedical share (profile) to the sample depot.
In the course of a heavy financing round the society did Canadian dollar (CAD) to 12 millions in March 2006 a radical step and replaced executive committee and supervisory board. Thus it wants to set the focus after years of the development now completely purposefully on the commercialization. Proven experts, who had been and others already successfully in the sale at that time of the vaccine manufacturer ID Biomedical involved in GlaxoSmithKline, would form now the core of the new management. According to opinion of the analysts of MIDAS Research such a scenario is conceivable quite also with Response Biomedical.
The Canadian diagnostics developer has up-to-date eleven immunoassay based rapid tests for marketing certified. The clinical tests were marketed over the marketing partners 3M Healthcare, Roche Dx and Shionogie. Additionally sell Response Biomedical in self-direction test for agents at government organizations and can from orders hardly save itself at present. Co-operation with the strong marketing partners shows in the meantime first positive effects: Roche Dx began in April 2009 with the marketing of the Kardio rapid tests in the USA, whereby the conversions " Clinical Products" already in the 2nd quarter around 370% are upward shot. The analysts of MIDAS Research would already prognosticate a substantial gross income increase of CAD 5 millions on CAD 11 million for this reason for 2009. During a further expected turnover doubling on CAD Response Biomedical will presumably reach 24 millions 2010 the profit area. In the coming weeks expect one move new flow. The analysts of MIDAS Research would therefore expect a strong upward motion already shortly. On view of twelve to 24 months they would think capable of to the share certificate even a smooth doubling, whereby the paper would be still clearly too cheap in the comparison to the Peergroup (e.g. Quidel) even then.
In view of this striking underestimation and the chance for short term profits on exchange the experts of " pack themselves; Global Biotech Investing" immediately a tidy position of the Response Biomedical share into their sample depot.
http://www.ariva.de/news/Response-Biomedical-Musterdepotaufnahme-Global-Biotech-Investing-3092419
CDC H1N1 Flu Update
2009 H1N1 Flu (Swine Flu)
http://www.cdc.gov/h1n1flu/
Response Biomedical to Present at Rodman & Renshaw Annual Global Investment Conference
Tue, 8 Sep 2009 12:01:00 UT
Response Biomedical Corporation announced today that S. Wayne Kay, Chief Executive Officer, will present a corporate update at the Rodman & Renshaw 11th Annual Healthcare Conference as part of Rodman and Renshaw’s Annual Global Investment Conference on Wednesday, September 9, 2009 at 5:20 p.m. Eastern time (2:20 p.m. Pacific time) at the Palace Hotel in New York City. A Web cast of the presentation will be available
More info about Response :
www.responsebio.com
Businesswire
Response Biomedical Obtains Special 510(k) U.S. FDA Clearance to Add Analytical Reactivity Information for the 2009 H1N1 Influenza A Virus to the RAMP® Influenza A/B Assay Package Insert
* Press Release
* Source: Response Biomedical Corporation
* On 7:30 am EDT, Thursday October 22, 2009
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company has been granted a Special 510(k) U.S. FDA clearance for an update to the Company’s RAMP® Influenza A/B Assay Package Insert to include analytical reactivity information for a strain of the 2009 H1N1 virus cultured from positive respiratory specimens. The RAMP® Influenza A/B Assay is marketed in the United States by 3M Health Care as the 3M™ Rapid Detection Flu A+B Test and is used to identify influenza A and B in human specimens.
Although the RAMP® Influenza A/B Assay has been shown to detect the 2009 influenza A (H1N1) virus in cultured isolates, the performance characteristics of this device with clinical specimens that are positive for the 2009 influenza A (H1N1) virus have not been established. The RAMP® Influenza A/B Assay can distinguish between influenza A and B viruses, but it cannot differentiate influenza subtypes.
“We are very cognizant of physicians’ needs to quickly diagnose influenza and improve patient care in light of a potential influenza pandemic,” said S. Wayne Kay, Chief Executive Officer. “This clearance further validates our technology and combined with our recent RSV clearance will give 3M additional tools to promote the 3M™ Rapid Detection platform to hospitals, which help play a critical role in diagnosing and containing any upper respiratory infection outbreak.”
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
The RAMP® system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP® clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through our commercial partners, Roche and 3M Health Care respectively.
In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
Response Biomedical is a publicly-traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at
www.responsebio.com.
Info on the new test
For anyone interested in the MR-proADM test, here is an article that gives quite a lot of color on the pros and cons of the test. I am left with the impression that this test may theoretically have some utility prognostically; but I doubt it has much utility with clinical decision making. The test may actually be very similar to NT-pro BNP or BNP. But, the study suggests that the clinical endpoint was mortality from heart failure. As such, it seems the test is not suited to answer the more germane clincal question, "Does this patient have heart failure or some other diagnosis causing his symptoms?"
The link may require registration:
http://www.theheart.org/viewArticle.do?primaryKey=919885
MR-proADM better prognostic tool than BNP, but not everybody convinced of biomarker's merit
November 11, 2008 | Michael O'Riordan
New Orleans, LA - A novel biomarker of vascular status is a better predictor of mortality at three months than brain natriuretic peptide (BNP) in acute heart-failure patients presenting at the emergency department with shortness of breath. The use of mid-region pro-adrenomedullin (MR-proADM) was also a better predictor of mortality than N-terminal pro-BNP (NT-proBNP), and these data suggest that MR-proADM can help triage very high-risk heart-failure patients who should be treated intensively.
"This new biomarker is superior to the best existing prognostic tool we have," lead investigator Dr Stefan Anker (Charité University Medical School, Berlin, Germany) told heartwire. "I can tell you that emergency-room physicians want to triage patients. We believe that using it would result in fewer patients being admitted to the hospital and would also get patients out of the hospital more quickly. Using this new biomarker would be cost-effective and save the healthcare system money."
You can't use this to put someone to the front of the line, because everyone is already at the front of the line.
Presenting the results of the Biomarkers in the Assessment of Congestive Heart Failure (BACH) trial here at the American Heart Association 2008 Scientific Sessions, Anker said the routine assessment of MR-proADM "can help identify patients who should move to the front of the line of medical care."
During a morning press conference, however, Dr Milton Packer (University of Texas Southwestern, Dallas, TX), the scheduled discussant during the late-breaking clinical-trials session, challenged the interpretation of the BACH investigators.
"We give every patient that comes into the emergency room optimal medical care, whether or not the prognosis indicates a high risk of death or a very high risk of death," Packer told the media. "Both of those [types of patients] get optimal medical therapy. The truth is you can't use this to put someone to the front of the line, because everyone is already at the front of the line. . . . This marker doesn't add very much to existing biomarkers, and it doesn't change our clinical management of patients."
Improving prognostic power in acute heart failure
During his presentation, Anker said that ADM is a peptide hormone that acts as a vasodilator and plays important roles in microcirculation and endothelial dysfunction. MR-proADM is a stable and surrogate marker for ADM release, something that occurs in endothelium dysfunction.
In this study, the BACH researchers wanted to test whether measuring MR-proADM is better than BNP in predicting 90-day mortality in patients who presented to the emergency department with shortness of breath. In total, 1641 patients were enrolled in the study, of whom 568 were diagnosed with acute heart failure. Patients were 64 years old and had a range of comorbidities, including 36% with a history of heart failure, 19% with prior acute MI, and 29% with diabetes mellitus.
At 90 days, the prognostic accuracy of MR-proADM was 73.5% compared with 60.8% for the measurement of BNP levels (p<0.001). In terms of secondary end points, the BACH researchers showed that MR-proADM was also a better predictor of 90-day mortality than NT-proBNP. In an analysis of MR-proADM by quartiles, patients with the highest levels, those with MR-proADM measurements >2.07 pmol/L, had a threefold higher risk of dying at 90 days than those in the lowest three quartiles.
Debating the merits of MR-proADM
Commenting on the findings, Packer noted that BNP isn't a particularly good biomarker for heart-failure prognosis and that physicians do best when assessing and predicting prognosis based on routine clinical assessment. He also questioned whether there was a need for MR-proADM, especially since knowing the patient's level is not going to change clinical care.
It is important to know that this particular patient might have outcomes that aren't quite as encouraging.
"The emergency-room physician is in charge of making a diagnosis and not with making a prognosis," said Packer. "The management of these patients is not changed one iota if you categorize them as very high risk or high risk . . . but, assuming the emergency-room physician didn't know that, and he wanted to use this test as a triage and would give optimal medical therapy only to patients with a high value. Here is my proposal: draw the test, send it to the lab, suppress the value and send back a very high value in everyone so that everyone would get optimal medical care. The truth is that if this is a mechanism of triage for medical care, I would personally like to see all of my patients have high value. Otherwise, it makes no sense."
Dr Clyde Yancy (University of Texas Southwestern, Dallas, TX) said the MR-proADM test presents an opportunity to more precisely diagnose patients, particularly when the initial presentation is ambiguous. "It also helps us understand who is at high risk," he said. "There is some importance in knowing who is at high risk, regardless of whether you can change therapy. It is important to know that this particular patient might have outcomes that aren't quite as encouraging."
Like Packer, Yancy said the stumbling block with these tests is how the new information is applied. "If you don't have a treatment strategy that would be exclusive for the patient at high risk, then one could argue that identifying risk per se doesn't help you."
Referring to Packer, Anker said: "I wish he were right in that all people would be as good at assessing the prognosis based on their clinical judgment and biomarkers as he would probably be in the emergency room." Physicians need biomarkers to aid their clinical judgment, he added, something that has been recognized by medical societies and the Food and Drug Administration and that has allowed for studies and the development of various tests, including the gold standard BNP.
New test
Without digging deeper , the PR doesn't give enough info to say whether this is a signif advance over BNP and NT-proBNP testing. Indeed, the PR doesn't even say whether the two tests have gone head to head in a trial.
There sure doesn't seem to be any likelihood of near term good news priced into Response the way it is trading lately.
New cardiac test...
http://www.reuters.com/article/scienceNews/idUSTRE4AA42N20081111
"I think that this is clearly significantly better than what we have now," Dr. W. Frank Peacock of the Cleveland Clinic, one of the study's lead investigators, said in an interview. "It raises the bar."
The Brahms test was approved for use in Europe on October 1. Nils Morgenthaler, the company's vice president for global medical affairs, said this study would be part of a package Brahms will submit to the U.S. Food and Drug Administration by the end of this year as it seeks approval in the world's biggest market.
"If approved in the U.S., the MR-proADM test will help ensure patients are accurately diagnosed and rapidly receive the treatment they need," Peacock said.
Results of the study were presented at the American Heart Association scientific meeting in New Orleans.
Morgenthaler said the company would be open to licensing its test to one of the larger diagnostic companies, such as Roche Holding AG. He also said Brahms was likely to become a public company in the foreseeable future."
A nice article on BNP and NT-ProBNP from hippyboy1 on the Stockhouse site.
http://www.smw.ca/docs/pdf200x/2007/01/smw-11614.PDF
http://www.stockhouse.com/Bullboards/MessageDetail.aspx?s=RBM&t=LIST&m=23590538&l=0&pd=1&r=0
Nt-ProBNP Clearance in US
http://micro.newswire.ca/release.cgi?rkey=1607226409&view=31910-0&Start=0
Estimates for the selling price per test are from $20 to $30 per test.
RBM is charging Roche approx 30% TO 40% of this final selling price.
The cost to manufacture each test?... 50% of the transfer price?
Total current manufacturing capability.. 15 million tests/year
http://www.haywood.com/pdffiles/RBMJul222008.pdf
Haywood's new report on RBM with comments and valuation updates given the Roche deal.
http://www.haywood.com/pdffiles/RBMJun272008.pdf
Note new price target is $1.60 up $0.5
Hi Urche
I guess I have mixed feelings about the announcement. No upfront cash which is bad because they will need money but Roche certainly wants to be a player in this market so thats a big plus.
As far as people buying the stock based on the empty press release I believe it was based on the fact that RBM said they were going to get a large partner to distribute their product.. and they did as they said.
They said they would get the flu test approved and they did.
They said the NT-Pro-BNP approval will come after the parter.. guaranteed to happen now
I find it interesting that Roche abandoned their own POC test in favor of RBM's.
Sounds like a big deal for Response.
And the volume was pretty yest, even if price didn't move much.
I am trying to understand why anyone would buy or sell Response based on that PR which was as devoid of meaningful details as any PR could be. I almost feel the company need not have bothered to put out the PR.
Did anyone listen to the conf call for analysts yesterday or otherwise learn any details of the deal with Roche?
Urche
Roche is their Cardiac partner.
http://biz.yahoo.com/prnews/080626/to316.html?.v=45
From the Stockhouse site:
http://clinicaltrials.gov/ct2/show/NCT00541632?spons=%223M%22&spons_ex=Y&rank=2
MRSA trial canceled. Have no idea why beyond the "performance variability" note.
Looking back at some of the old trial results they appeared promising. Don't know whether it was a problem with some of the clinics or whether it was the test.
Hi Urche
I think its almost exactly 30 minutes as the buzzer to end the session goes off just as he is finishing his presentation.
Thanks for the reminder about the webcast.
About how long was it---so I can figure out a time to listen.?
Nice presentation today with a bit of new news. Still on track for a 2nd quarter partnership with a company that is larger than 3M for the cardiac marker distribution.
The next 3M test is going to be RSV.
They are talking with other companies about partnerships for cancer markers and kidney tests.
3M's PR on Rapid Detection Flu A+B Test
http://www.bio-medicine.org/medicine-news-1/3M-Health-Care-announces-new-3M-Rapid-Detection-Flu-A+B-test-17415-1/
A long time coming....
I've forgotten the filing date, but I think it was about a year from filing to approval!
Timing seems sufficient for 3M to get some customers in US for the RAMP flu test prior to the 2008-9 flu season.
What is the next milestone for this company?
urche
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
172
|
Created
|
06/16/04
|
Type
|
Free
|
Moderators |
call toll-free in North America 1.888.591.5577 outside North America call +1.604.456.6010
Response Biomedical Corporation
1781 - 75th Avenue W.
Vancouver, BC
V6P 6P2 CANADA
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
The RAMP® system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP® clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through our commercial partners, Roche and 3M Health Care respectively.
In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
Response Biomedical is a publicly-traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
"I am very pleased to be leading Response Biomedical at this exciting time in the evolution of the Company. With partnerships in place with 3M Company, Roche Diagnostics and Shionogi & Co. Ltd., we are poised for strong growth. We also announced a new collaboration to develop a diagnostic for TB. We have begun working with FIND, a Bill and Melinda Gates-funded organization and we are excited about this and other future opportunities we continue to explore.
We are fortunate to be housed in a state-of-the-art manufacturing and product development facility. This global Headquarters will allow us to scale-up manufacturing to meet the needs of our current and future business partners and customers.
We have begun to see our major clinical tests launched into the marketplace by our partners. 3M launched the Flu A+B Test in October 2008 and Roche Diagnostics, the largest in vitro diagnostics company in the world, has now launched the cardiovascular line of products.
These are the building blocks which I believe will significantly enhance shareholder value while recognizing the extraordinary accomplishments of our Response Biomedical Team as a leader in the rapid point-of-care diagnostics marketplace."
S. Wayne Kay, CEO
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company has been granted a Special 510(k) U.S. FDA clearance for an update to the Company’s RAMP® Influenza A/B Assay Package Insert to include analytical reactivity information for a strain of the 2009 H1N1 virus cultured from positive respiratory specimens. The RAMP® Influenza A/B Assay is marketed in the United States by 3M Health Care as the 3M™ Rapid Detection Flu A+B Test and is used to identify influenza A and B in human specimens.
Although the RAMP® Influenza A/B Assay has been shown to detect the 2009 influenza A (H1N1) virus in cultured isolates, the performance characteristics of this device with clinical specimens that are positive for the 2009 influenza A (H1N1) virus have not been established. The RAMP® Influenza A/B Assay can distinguish between influenza A and B viruses, but it cannot differentiate influenza subtypes.
“We are very cognizant of physicians’ needs to quickly diagnose influenza and improve patient care in light of a potential influenza pandemic,” said S. Wayne Kay, Chief Executive Officer. “This clearance further validates our technology and combined with our recent RSV clearance will give 3M additional tools to promote the 3M™ Rapid Detection platform to hospitals, which help play a critical role in diagnosing and containing any upper respiratory infection outbreak.”
Clinical Products Revenues Grow 373% over Q2 2008
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX:RBM) (OTCBB:RPBIF) reported that clinical products revenue for the three and six month periods ended June 30, 2009 increased 373% and 208% to $1,805,308 and $3,548,014, respectively, compared to $381,615 and $1,150,760 for the same periods in 2008. Total revenues for the second quarter increased 174% from the same quarter in 2008, from $997,515 in Q2/2008 to $2,735,415 in Q2/2009.
For the three and six month periods ended June 30, 2009, the Company reported a loss of $1,898,987 or $0.01 per share and $3,630,402 or $0.02 per share, respectively, compared to a loss of $3,740,494 or $0.03 per share and $7,284,605 or $0.05 per share for the same periods in 2008. This decrease in the loss for the three and six months period ended June 30, 2009 of 49% and 50%, respectively, is primarily due to higher gross profit on product sales, higher contract service fee and revenues from collaborative research arrangements and reduced expenses across all departments.
“We are continuing to show strong results as we work with our partners to introduce our rapid point-of-care (POC) diagnostic tests to an expanding market,” said S. Wayne Kay, CEO, Response Biomedical. “We had the second consecutive quarter with the highest revenues for any quarter in the Company’s history. These strong financial results for the first half of 2009 ensure we remain on track to finish the year with record revenues.”
News Releases:
www.responsebio.com/newswire.asp
Why wait days for lab results? Save time by using RAMP for quick pre-screening. Now you can effectively manage your WNV program in a timely manner.
The RAMP WNV Test was independently validated by the US Center for Disease Control (CDC) and Canadian National Microbiology Lab (NML) to confirm:
RAMP is
, takes minutes to set up and results are easy to interpret. There is no calibration or maintenance required.
Learn more about how the RAMP System works
.
No manual recording of results. Up to 500 results can be stored in the RAMP reader memory and printed or uploaded to your computer. You can e-mail your data by saving it as a Microsoft excel file and sending as an attachment.
Title : Response Biomedical Q3 Update
Date : Tuesday November 10th, 2009 at 10:00 AM ET
Event Details:
Response Biomedical Corp. engages in the research, development, commercialization, and distribution of diagnostic technologies for the medical point-of-care (POC) and on-site environmental testing markets. It provides a technology called Rapid Analyte Measurement Platform (RAMP), which is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test. The company's RAMP tests are used in the early detection of heart attack, congestive heart failure, environmental detection of West Nile Virus, and biodefence applications, including the rapid onsite detection of anthrax, smallpox, ricin, and botulinum toxin.
Response Biomedical also develops and manufactures RAMP immunoassays for clinical, pharmaceutical, industrial, environmental, and agricultural applications. It has operations in Canada, the United States, and Asia. The company was founded in 1980 and is based in Burnaby, Canada.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |